Latest Pharma Insights
BMS Sees Growth Products’ Contributions To Total Revenue Increase In Q3
Bristol Myers Squibb Company’s third quarter earnings on 31 October built on the progress that the big pharma reported in its second quarter financials. In both reports, revenue exceeded analyst expec
Scrip - October 31, 2024
Bristol Myers Squibb Company’s third quarter earnings on 31 October built on the progress that the big pharma reported in its second quarter financials. In both reports, revenue exceeded analyst expec
Scrip - October 31, 2024
Merck Winning With Winrevair, Guarded On Gardasil In Q3
Seven months after its US Food and Drug Administration approval, Merck & Co.’s pulmonary arterial hypertension (PAH) drug Winrevair (sotatercept) has already beat sales estimates, getting it close
Scrip - October 31, 2024
Seven months after its US Food and Drug Administration approval, Merck & Co.’s pulmonary arterial hypertension (PAH) drug Winrevair (sotatercept) has already beat sales estimates, getting it close
Scrip - October 31, 2024
BioFuture Notebook: Struggling With Innovation, Financing And Reimbursement
The BioFuture conference in New York featured panels that got into the nitty-gritty of drug development – from using artificial intelligence to improve the efficiency of drug development, to finding i
Scrip - October 31, 2024
The BioFuture conference in New York featured panels that got into the nitty-gritty of drug development – from using artificial intelligence to improve the efficiency of drug development, to finding i
Scrip - October 31, 2024
Madrigal Shatters Street Expectations With $62m In Q3 Rezdiffra Sales
During the early launch months for Rezdiffra (resmetirom), Madrigal Pharmaceuticals is thinking both about the present and the future – juggling goals to build a market with the first approved drug fo
Scrip - October 31, 2024
During the early launch months for Rezdiffra (resmetirom), Madrigal Pharmaceuticals is thinking both about the present and the future – juggling goals to build a market with the first approved drug fo
Scrip - October 31, 2024
Summit Doubles Down On Lung Cancer With Ivonescimab Trial Expansion
Summit Therapeutics has a potential blockbuster successor to Keytruda in the shape of PD-1/VEGF bispecific ivonescimab, and has now expanded its key Phase III lung cancer study to maximize its opport
Scrip - October 31, 2024
Summit Therapeutics has a potential blockbuster successor to Keytruda in the shape of PD-1/VEGF bispecific ivonescimab, and has now expanded its key Phase III lung cancer study to maximize its opport
Scrip - October 31, 2024
AstraZeneca Leads The Way In Clinical Trials
AstraZeneca ended last year as the world’s seventh largest pharma company by market cap – but as the leading group when it comes to starting clinical trials. Last year AstraZeneca kicked off 139 tri
Scrip - October 31, 2024
AstraZeneca ended last year as the world’s seventh largest pharma company by market cap – but as the leading group when it comes to starting clinical trials. Last year AstraZeneca kicked off 139 tri
Scrip - October 31, 2024
Amgen Reinvests Sales Gains In R&D As Phase II MariTide Readout Approaches
Amgen Inc. is taking its strong profits from the third quarter and reinvesting a significant portion of its sales gains in potential future growth drivers, most notably its closely watched obesity con
Scrip - October 31, 2024
Amgen Inc. is taking its strong profits from the third quarter and reinvesting a significant portion of its sales gains in potential future growth drivers, most notably its closely watched obesity con
Scrip - October 31, 2024
Cipla Signals Lanreotide Supply Strain, Eyes First Wave GLP-1 India Entry
Cipla flagged up supply-related strains for its lead peptide asset, lanreotide injection, in the US, with the impact seen spilling into the next quarter, even as the company readies a number of growth
Scrip - October 31, 2024
Cipla flagged up supply-related strains for its lead peptide asset, lanreotide injection, in the US, with the impact seen spilling into the next quarter, even as the company readies a number of growth
Scrip - October 31, 2024